News

Microbiological Considerations in Cleanroom Validation: Application Note Published in European Pharmaceutical Review

Wickham Laboratories Ltd is delighted to announce our most recent technical article on, “Microbiological Considerations in Cleanroom Validation”, which has been featured in European Pharmaceutical Review’s December 2018 issue.

Microbiological contamination is a major safety concern within the manufacturing and development of all pharmaceutical & medical devices. This article discusses how and why a cleanroom environment plays an important role during these processes.

An excerpt of this article as follows:

Boyds supports growth vision with new Clinical and Medical Affairs Group

Boyds, a leading consultancy business supporting the development of pharmaceutical and biotech products for patient benefit, has set up a Clinical and Medical Affairs Group to provide pharmaceutical medicine and medical monitoring support to its clients and their programmes.

Dr Lalitha Mahadavan has been appointed as Director of Clinical and Medical Affairs and will head up the Cambridge-based Group, which will provide a multi-speciality consulting service to Boyds’ client portfolio.

February 2019 eNews

To view the February 2019 eNews click here

Mark Johnson joins The RSA Group as Partner

The RSA Group, a leading Life Sciences executive search firm, announced today that Mark Johnson has joined the company as a Partner. Mark is a respected life sciences search professional with particular expertise in the cell and gene therapy sector.

Moderna exercises option for an exclusive product license with Avacta Group plc

Cambridge, UK, 04 February 2019: Avacta Group plc (AIM: AVCT), the developer of Affimer^®biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. (NASDAQ: MRNA) has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.

Sosei Heptares announces Medicxi to invest up to €40 million in new collaboration based on its orexin agonist program

Tokyo, Japan and London, UK, 4 February 2019 – Sosei Group Corporation (“the Company”; TSE: 4565), announces it has entered into a structured financing agreement¹ with Medicxi, a venture fund dedicated to financing asset-centric companies, to form two independent companies, Orexia Limited (“Orexia”) and Inexia Limited (“Inexia”), that aim to develop novel therapies based on positive modulators of the G protein-coupled receptors Orexin OX1 and OX2 for neurological diseases.

Certara Launches Version 18 of its Physiologically-based Pharmacokinetic (PBPK) Simcyp Simulator

PRINCETON, NJ – Jan. 29, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 18 of its Simcyp® Population-based Simulator.

“I am delighted to introduce Simcyp Simulator v18, which includes several major modeling and simulation advances to help improve the safety and efficacy of new drugs – both small molecules and biologics – under development,” said Certara’s Simcyp President and Managing Director Steve Toon, PhD.

Metrion Biosciences and LifeArc sign collaboration agreement for neuroscience-focused ion channel drug discovery

Cambridge and London, UK, 29 January 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK medical research charity, today announced they have entered into a collaboration agreement for an ion channel drug discovery project in the field of neuroscience. The project aims to identify novel selective small molecule modulators of a specific ion channel target, which human patient gene association studies have identified as likely to be involved in neurological pathogenesis.

Horizon Discovery and Rutgers University form exclusive partnership to develop next generation novel gene editing technology

Cambridge, UK, 28 January 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Group”), a global leader in gene editing and gene modulation technologies, today announces that it has entered into an exclusive strategic partnership with Rutgers, The State University of New Jersey (US), to develop and commercialise a novel gene editing technology, known as base editing. The technology potentially has applications in the development of new cell therapies and will augment Horizon’s research tools and services.

Women in Pharma - Are We There Yet?

The pharma industry has changed dramatically in recent decades, not only in terms of the vast strides that have been made in science, but also in terms of the leadership landscape. In the 1970s, it was highly unlikely that a woman would be running one of the world’s largest pharma companies, and today we have Emma Walmsley at the helm of GlaxoSmithKline.

My Account